公司資料

Biohaven 股價、新聞與催化劑

股票代碼:
BHVN
交易所:
NYSE
產業:
Biopharma
所在地:
United States

股票表現

14.46 USD (-1.23%)

收盤價

最後更新: 2026年8月17日

1.53B USD

市值

股價為何變動

As of Aug 17, 2026, BHVN closed down 1.23% at $14.46. No new same-company headline was identified in the current news window.

公司概覽

業務概覽

Biohaven is a biopharmaceutical company focused on neuroscience, immunology, and rare disease. Its business combines commercial assets with a pipeline aimed at multiple specialty indications.

所在地與產業分類

Biohaven is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a strong neuroscience footprint.

商業模式特徵

The company depends on product sales, launch execution, and pipeline expansion across CNS and immune-mediated disease. Investors watch revenue, development milestones, and strategic execution.

生技產業定位

Biohaven occupies a premium specialty-biopharma niche within biotech. It has both commercial grounding and catalyst sensitivity, which keeps the stock lively.

未來催化劑

  • Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story. The company remains one of the cleaner CNS growth names if execution holds.

近期新聞

    相似股票

    商業成熟度、治療領域或催化劑模式相近的同業公司。